Angiogenesis is a critical process in numerous diseases, and intervention in neovascularization has therapeutic value in several disease settings, including ocular diseases, arthritis, and in tumor progression and metastatic spread. Various vascular targeting agents have been developed, including those that inhibit growth factor receptor tyrosine kinases, blocking antibodies that interfere with...

HER2-targeted therapy has moved beyond trastuzumab to include other monoclonals targeting the cell surface, receptor tyrosine kinase inhibitors of HER2, and antibody-drug conjugates. Afatinib, a small molecule receptor tyrosine kinase inhibitor, now joins the ranks of HER2-targeting agents in combination with trastuzumab. The combination brings new opportunities and challenges.

Objective(s):miR-125b has been identified as a tumor suppressor in many tumors, but its role in giant cell tumor (GCT) of bone remains poorly understood. The current study aimed to investigate the potential role and mechanism of miR-125b in GCT. Materials and Methods:Expression levels of miR-125b in GCT tissues were determined using RT-PCR. The cell proliferation was surveyed by direct cell coun...

Vascular endothelial growth factor receptor-2 (VEGFR-2); a cell surface receptor for vascular endothelial growth factors, is a key pharmacological target involved in the cell proliferation/angiogenesis. It has been revealed that VEGFR-2 induces proliferation through activation of the extracellular signal-regulated kinases pathway. In this regard, targeting the VEGFR-2 has been considered as an ...

objective(s):mir-125b has been identified as a tumor suppressor in many tumors, but its role in giant cell tumor (gct) of bone remains poorly understood. the current study aimed to investigate the potential role and mechanism of mir-125b in gct. materials and methods:expression levels of mir-125b in gct tissues were determined using rt-pcr. the cell proliferation was surveyed by direct cell coun...

introduction: in continuation of recent development of possible c-x-c chemokine receptor type 4 (cxcr4) imaging agents, we report the development of a possible cxcr4 targeted therapy agent. methods: [153sm]labeled 1,1′-[1,4-phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclo -tetradecane ([153sm]-amd3100) was prepared using [153sm]smcl3 and amd-3100 for 24h at 50°c in acetate buffer.stability ...

expression of receptor tyrosine kinase ror1 in a wide variety of cancers has emerged as a new era focusing on targeting this receptor in cancer therapy. our preliminary re-sults indicate the presence of a truncated transcript of ror1 in tumor cells. the trun-cated ror1 encompasses extracellular and transmembrane domains, lacking catalytic kinase domain (ror1-ecd). as enzyme activity is highly d...